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Abstract
Background: The Xpert® MTB/RIF (XP) has a higher sensitivity than sputum smear microscopy (70% versus 35%) for
TB diagnosis and has been endorsed by the WHO for TB high burden countries to increase case finding among HIV
co-infected presumptive TB patients. Its impact on the diagnosis of smear-negative TB in a routine care setting is
unclear. We determined the change in diagnosis, treatment and mortality of smear-negative presumptive TB with
routine use of Xpert MTB/RIF (XP).
Methods: Prospective cohort study of HIV-positive smear-negative presumptive TB patients during a 12-month
period after XP implementation in a well-staffed and trained integrated TB/HIV clinic in Kampala, Uganda. Prior to
testing clinicians were asked to decide whether they would treat empirically prior to Xpert result; actual treatment
was decided upon receipt of the XP result. We compared empirical and XP-informed treatment decisions and
all-cause mortality in the first year.
Results: Of 411 smear-negative presumptive TB patients, 175 (43%) received an XP; their baseline characteristics did
not differ. XP positivity was similar in patients with a pre-XP empirical diagnosis and those without (9/29 [17%]
versus 14/142 [10%], P = 0.23). Despite XP testing high levels of empirical treatment prevailed (18%), although XP
results did change who ultimately was treated for TB. When adjusted for CD4 count, empirical treatment was not
associated with higher mortality compared to no or microbiologically confirmed treatment.
Conclusions: XP usage was lower than expected. The lower sensitivity of XP in smear-negative HIV-positive
patients led experienced clinicians to use XP as a “rule-in” rather than “rule-out” test, with the majority of patients
still treated empirically.
Keywords: Empirical treatment, Molecular diagnostic techniques/methods, Tuberculosis, pulmonary/diagnosis,
Tuberculosis, pulmonary/epidemiology, HIV Infections/complications
Background
Tuberculosis (TB) remains the main cause of death
among HIV-infected patients in sub-Saharan Africa.
Sputum smear microscopy has a low sensitivity for
detecting TB particularly among people living with HIV.
Because of its low cost, it is the mainstay of diagnosis in
many high burden countries. In December 2010 the
World Health Organization (WHO) endorsed Xpert®
MTB/RIF (Cepheid, Sunnyvale, California, USA) (XP)
[1], the first fully automated, real-time nucleic acid
amplification technology for the rapid detection of TB
[1, 2] which can be performed with only 1 day of
training by most health care workers. A WHO policy
statement came out in 2011 recommending its use as
the initial diagnostic test among people suspected of
multi-drug resistant (MDR) or HIV-associated TB [2].
WHO policy updates in October 2013 recommending
broad use of Xpert for TB diagnosis [3] and concessionary
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pricing for high-burden countries have resulted in wide-
spread roll-out in routine care settings [4].
Because of a higher sensitivity than sputum smear
microscopy and a running time of two hours, routine
use of XP was predicted to increase case finding and
improve TB treatment outcomes [5–7]. However, this
impact has not been realized in trials to date [8–11].
Some have argued that the impact may been blunted by
high rates of empirical treatment in sub-Saharan Africa:
up to 40% of TB cases are treated empirically due to
diagnostic uncertainties and the risk of severe morbidity
and mortality if TB treatment is delayed [12]. It is
therefore still unclear what impact XP will have on case
finding and TB treatment outcomes in routine care
settings [13]. To date no studies have investigated the
impact of XP on health care workers’ pre- and post-test
management [13].
In an integrated TB-HIV clinic with adequate staffing
and training in Kampala, Uganda, we implemented XP
for use as an add-on test in sputum smear negative
presumptive TB patients. We investigated if and how
clinicians changed their diagnostic decision-making on
the basis of the additional test available to them. Consid-
ering the high level of experience of the clinicians, we
hypothesized that this would be limited. We analyzed
XP usage and yield compared to empirical diagnosis
without access to XP, and examined treatment decisions
subsequent to an XP result. We also compared mor-
tality in the first year after being investigated for TB
between patients who were treated empirically, treated




This study was performed at the integrated adult TB/
HIV clinic of the Infectious Diseases Institute, part of
the Makerere University College of Health Sciences
located at Mulago Hospital in Kampala, Uganda. This
clinic has been described in detail previously [14, 15]. In
brief, this clinic provided a one-stop-shop outpatient TB
and HIV service for all patients suspected of having TB
among the over 30,000 registered HIV-positive patients
of the Adult Infectious Diseases Clinic. It is staffed by
medical officers, nurses and counsellors who provide
care for both TB and HIV during the same clinic visit.
All patients were screened for TB symptoms in the
overall HIV clinic waiting area, in accordance with
guidelines of the WHO and the Ugandan Ministry of
Health [15]. Those who screened positive were referred
to the TB/HIV clinic, where the clinicians followed local
guidelines to diagnose TB. At the time of the study, 2
sputum samples were tested with smear microscopy,
one collected immediately and one on the following
morning. Additional available investigations included
chest X-ray, lymph node aspirate and abdominal
ultrasound where applicable (fee-for-service). Sputum
cultures were not routinely available. Treatment of
smear-negative patients was based on the clinician’s
interpretation of any ongoing symptoms and the chest
X-ray. Prior to XP implementation, 22% of patients
treated for TB were smear-negative [14, 15]. At the
time of the study, although the green light committee
of the WHO had approved Uganda for multi-drug
resistance (MDR) TB treatment, drugs were not yet
available. All patients in whom MDR was detected
were referred to the national TB clinic in Mulago
Hospital, to await the arrival of the drugs.
Study design and population
This was a prospective cohort study in which we
included all presumptive TB patients of the TB/HIV
clinic who were sputum smear microscopy negative
from 1 May 2012–1 May 2013. Clinicians could order
an XP using a request form which included the following
question: “with the current clinical and diagnostic infor-
mation available to you, would you start this patient on
TB treatment?”, which was to be answered by ticking a
box either “yes” or “no”. Clinicians were trained how to
use the form and there were ongoing checks of their
understanding. The XP was performed immediately
while the patient waited for the results. The result was
returned to the clinician; the request forms were
retained in the laboratory. Treatment was initiated on
the same day according to the clinician’s interpretation
of the XP result. Patients were followed up for 1 year to
determine their outcome.
Ethical review statement
The Adult Infectious Diseases Clinic has ongoing
approval by the Makerere University Research Ethics
Committee and the Uganda National Council of Science
and Technology to utilize routinely collected data for
operational research purposes. A written consent waiver
to do retrospective analysis of routinely collected data
was granted; data were analysed after removal of unique
personal identifiers.
Data management and definitions
The results on the XP laboratory request forms were
entered into a study database by a laboratory technician
and then merged with routinely collected clinical, diag-
nosis and treatment electronically collected data of the
TB/HIV clinic. A pre-XP empirical diagnosis was defined
as the intention to treat for TB before access to the XP
result (at the time of XP request). Post-XP empirical TB
treatment was defined as the decision by a clinician to
treat for TB without a positive XP result. We further
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categorized patients according to their final diagnostic
and treatment profile: TB treatment on the basis of
microbiological confirmation (positive XP), post-XP
empirical treatment (negative or no XP) or no treatment
(negative or no XP).
During the period of our study the CD4+ T cell (CD4)
counts were only determined once a year. We therefore
used the closest measurement within 6 months before
or after the date of presentation as a presumptive TB
patient. HIV viral load monitoring was not routinely
available.
Statistical methods
We used descriptive statistics for the baseline character-
istics of the study population at first presentation to the
TB clinic, and to determine XP usage (the proportion of
patients who were evaluated with XP) and to compare
diagnostic and treatment decisions. Differences were
tested using Chi-2, Fisher’s Exact, Student’s t-test,
Kruskal-Wallis or Wilcoxon rank sum tests, as appropri-
ate. Logistic regression was used to calculate the odds
ratio of TB treatment by pre-XP empirical diagnosis,
overall and stratified by XP result. To prevent over-
fitting of the model due to the small number of out-
comes in this group only multivariable analyses with two
independent variables was done. Survival analysis, the
log-rank test for equality of survivor functions and Cox
regression were used to compare mortality in the first
year after the presentation at the TB/HIV clinic by
the different diagnostic and treatment profiles. The
proportional hazards assumption was checked using
log(−log(survival)) curves and Schoenfeld residuals.
Adjusted hazard ratios (aHR) of the risk of death in
the first year were calculated using Cox regression
and adjusting for a priori risk factors (sex, CD4 count
and ART at date of presumptive TB). Age was omit-
ted due to risk of over-fitting; initial univariable
analysis showed no association however. Data were
analysed using STATA 12.0 SE (StataCorp, College
Station, Texas, USA).
Results
A total of 495 patients were evaluated for tuberculosis
with a sputum smear between 1 May 2012 and 1 May
2013. Of these, 84 (17%) were sputum smear-positive.
The 411 (83%) patients who were sputum smear-
negative were included in this analysis. The median age
of the study participants was 38 years (interquartile
range 31, 44), 56% were female, 15% had been previously
treated for TB, 50% were on ART at the time of investi-
gation, and the median CD4 count at presentation was
275/mm3 (interquartile range, 141–440) (Table 1).
A flow diagram outlining the diagnostic process and
treatment decisions in the included patients is shown in
Fig. 1. Among the 411 smear-negative presumptive TB
patients, 175 (43%) were sent for an XP. There were no
technical problems with the machine during the study
period. There were no differences in baseline characteris-
tics between patients who did or did not receive an XP
test, including symptomatology at presentation (Table 1).
However, patients who underwent an XP received a chest
X-ray more often (94% versus 78%, P < 0.001) which was
more likely to be abnormal (69% versus 54%, P 0.008).
Patients who received an XP were equally likely to be
diagnosed with TB (23% versus 21%, P 0.59) as those who
did not, but were less likely to be diagnosed with extra-
pulmonary TB (17% versus 50%, P 0.001).
The minority of the patients for whom an XP was
requested received a pre-XP empirical diagnosis (29
[17%]). Nonetheless, there were no differences in baseline
characteristics among patients with and without a pre-XP
empirical diagnosis (Table 2). There was also no difference
in XP positivity (17% versus 10%, P = 0.23). We identified
rifampicin resistance in one of the patients without a pre-
XP empirical diagnosis.
There was a slight decrease in the total number of
patients who would have been treated empirically (from
79 [20%] pre-XP to 72 [18%] post-XP). However, these
were not the same individuals: 11 [38%] patients with a
pre-XP empirical diagnosis were treated compared to 28
[20%] patients without a pre-XP diagnosis (Fig. 1).
Patients with a pre-XP empirical diagnosis were more
likely to be treated for TB despite a negative XP (post-XP
empirical treatment, 7 [30%] versus 14 [11%], P = 0.014),
however this effect disappeared on adjusting to the CD4
count (adjusted odds ratio [aOR] 2.5 [95% confidence
interval, 0.8–8.0]; aOR per 50 cells/ul higher CD4 count
0.9 [95% CI 0.8–1.1]). There were no differences in base-
line characteristics between those who were and were not
treated empirically after a negative XP (Table 3), and no
risk factors of empirical treatment could be identified in
multivariable logistic regression (data not shown).
Whilst simple analysis of mortality in the first year
after presentation at the TB clinic was higher among
those treated empirically (with no or negative XP result)
compared to those treated with a positive XP or those
not treated at all (22% versus 5% and 9% respectively,
Fig. 2) there are multiple possible confounders of this
relationship. In multivariable Cox regression analysis,
adjusting for possible confounders that we had data for,
including CD4 count, sex and ART usage at presenta-
tion, no association between post-XP empirical treat-
ment or microbiologically confirmed treatment and the
hazard of death was found (aHR 1.8 [95% CI, 0.8–3.9],
and aHR 0.8 [95% CI, 0.1–6.3] respectively). For every
50 cells’ increase in CD4 count, it decreased by 18%
(aHR 0.8 [95% CI, 0.7–0.9], P < 0.001). Male sex was as-
sociated with higher mortality (aHR 2.7 [95% CI, 1.3–
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5.9]), but no association was found for ART usage at
presentation (aHR 0.5 [95% CI, 0.3–1.1]).
Discussion
This study investigated the impact of XP usage on the
diagnosis, treatment and mortality of HIV- positive
smear-negative presumptive TB patients. Despite current
WHO guidelines recommending the use of XP as the
first diagnostic test rather than as an add-on to a
negative sputum smear [3], this study offers insights into
clinicians’ diagnostic and treatment decisions with the
availability of XP and the associated treatment outcomes.
We found that XP was only used in 43% of eligible patients
despite free access to the test. The higher likelihood of an
X-ray being ordered in this same group of patients suggests
clinicians had a higher level of clinical suspicion compared
to those not sent for XP. High levels of empirical treatment
prevailed although XP testing did change who was ultim-
ately treated for TB. A pre-XP empirical diagnosis by an
experienced clinician did not predict XP positivity.
Although XP availability led to little change in the
total proportion of presumptive TB patients actually
treated for TB, the use of XP led to treatment of those
who would not have been treated pre-XP and vice versa.
Fig. 1 Flow diagram of study patients. A pre-XP empirical diagnosis was defined as the recorded intention to start treatment for TB without
access to XP (as determined by the clinician at the time of the XP request). TB, tuberculosis; XP, Xpert® MTB/RIF. *Invalid XP results in 2, 1 and 1
patients respectively. ^Patients treated empirically pre-XP. #Patients treated empirically post-XP. $1 patient died before being started on TB treatment
Table 1 Baseline characteristics of smear-negative presumptive TB patients, overall and by whether they had received an Xpert®
MTB/RIF
Characteristic No XP XP Total P-value
Total (n [%]) 236 (57.4) 175 (42.6) 411 (100)
Age (mean [SD]) 38 (9) 40 (11) 39 (10) 0.10
Female sex (n [%]) 133 (56.4) 99 (56.6) 232 (56.4) 0.97
CD4 count (median [IQR])* 274 (147, 422) 275 (179, 478) 275 (162, 426) 0.73
ART at TB treatment initiation (n [%]) 116 (49.2) 89 (50.9) 205 (49.9) 0.73
Prior TB treatment (n [%]) 34 (14.4) 29 (16.6) 63 (15.3) 0.55
Symptomatology at presentation (n [%]) Cough 228 (96.6) 173 (98.9) 401 (97.6) 0.14
Fever 169 (71.6) 124 (70.9) 293 (71.3) 0.87
Night sweats 112 (47.5) 88 (50.3) 200 (48.7) 0.57
Weight loss 80 (33.9) 63 (36) 143 (34.8) 0.66
Anorexia 113 (47.9) 84 (48) 197 (47.9) 0.98
Chest pain 64 (27.1) 57 (32.6) 121 (29.4) 0.23
IQR interquartile range, n number, SD standard deviation, TB tuberculosis, XP Xpert® MTB/RIF
*On 200, 152 and 352 patients, respectively
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Despite the clinicians’ experience, XP positivity was not
more likely among patients with than without a pre-XP
empirical diagnosis. This corroborates previous work on
the poor accuracy of empirical diagnoses (using sputum
culture as gold standard) in this clinic and in Tanzania
[16, 17]. Despite having access to all clinical data, we
were not able to determine which clinical factors most
influenced clinicians in their decision-making process
pre-XP. Among hospitalized patients, a recent study
in Kampala identified productive cough, fever and
tachycardia as predictors of empirical treatment [18].
The lack of sputum culture in our clinic precludes
the determination whether empirical treatment was
true- or false-positive (both pre- and post-XP).
Our data suggests that clinicians used the XP test as a
“rule-in” test and only partly as a “rule-out” test. This is
justifiable as the test is known to have low sensitivity as
an add-on test to a negative sputum smear (61% in a
HIV-positive population) [19, 20]. Nevertheless, the
clinicians decided against treatment in just over half of
the patients whom they would have treated without
access to an XP, which may indicate an overestimated
Table 3 Baseline characteristics of included smear-negative presumptive TB patients who had a negative Xpert® MTB/RIF result by
actual empirical TB treatment initiation
Characteristic Post-XP empirical Rx No post-XP empirical Rx Total P-value
Total (n [%]) 22 130 152
Age (mean [SD]) 36 (12) 41 (11) 40 (10) 0.04
Female sex (n [%]) 13 (59.1) 71 (54.6) 84 (55.3) 0.70
CD4 count (median [IQR])* 239 (139, 329) 289 (133, 456) 283 (133, 441) 0.25
ART at presentation 12 (54.5) 69 (53.1) 81 (53.3) 0.90
Prior TB treatment (n [%]) 1 (4.5) 25 (19.2) 26 (17.1) 0.09
Symptomatology at presentation (n [%]) Cough 21 (95.5) 129 (99.2) 150 (98.7) 0.15
Fever 16 (72.7) 91 (70) 107 (70.4) 0.80
Night sweats 11 (50) 61 (46.9) 72 (47.4) 0.79
Weight loss 10 (45.5) 38 (29.2) 48 (31.6) 0.13
Anorexia 13 (59.1) 55 (42.3) 68 (44.7) 0.14
Chest pain 8 (36.4) 42 (32.3) 50 (32.9) 0.70
IQR interquartile range, n number, Rx treatment, SD standard deviation, TB tuberculosis, XP Xpert® MTB/RIF
*On 17, 118 and 135 patients, respectively
Table 2 Baseline characteristics of smear-negative presumptive TB patients who received an Xpert® MTB/RIF by whether the
clinician would have treated them without access to the Xpert result or not




Missing response Total P-value
Total (n [%]) 142 29 4 175
Age (mean[SD]) 40 (11) 39 (9) 47 (11) 40 (11) 0.52
Female sex (n [%]) 80 (56.3) 16 (55.2) 3 (75) 99 (56.6) 0.75
CD4 count (median [IQR])* 280 (189, 483) 238 (132, 343) 403 (390, 983) 275 (179, 478) 0.66
ART at TB treatment initiation (n [%]) 72 (50.7) 16 (55.2) 1 (25) 89 (50.9) 0.53
Prior TB treatment (n [%]) 23 (16.2) 6 (20.7) 0 (0) 29 (16.6) 0.55
Symptomatology at presentation (n [%]) Cough 140 (98.6) 29 (100) 4 (100) 173 (98.9) 0.79
Fever 101 (71.1) 19 (65.5) 4 (100) 124 (70.9) 0.36
Night sweats 72 (50.7) 13 (44.8) 3 (75) 88 (50.3) 0.51
Weight loss 48 (33.8) 14 (48.3) 1 (25) 63 (36) 0.3
Anorexia 67 (47.2) 14 (48.3) 3 (75) 84 (48) 0.55
Chest pain 46 (32.4) 10 (34.5) 1 (25) 57 (32.6) 0.93
IQR interquartile range, n number, Rx treatment, SD standard deviation, TB tuberculosis, XP Xpert MTB/RIF
*On 124, 26, 2 and 152 patients, respectively
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confidence in a negative XP. This potential false sense of
security has also been described during roll-out of rou-
tine XP as the first-line diagnostic in South Africa [21].
This is likely to be exaggerated in rural areas where
more mid-level health care workers are present with
more limited TB diagnostic training [22]. In future, this
risk might be mitigated by use of the next generation
Xpert cartridge, the Xpert MTB/RIF Ultra, which has
been shown to have a higher sensitivity [23].
Low XP utilisation has also been described in a study
evaluating its use in 18 health facilities throughout
Uganda (21%) [24], as well as in studies from the
Democratic Republic of Congo (37%) and Swaziland
(51%) [25, 26]. It has been suggested that the varying
degrees of utilisation may be associated with the level of
training and support provided to health care workers
[24]. It may also take time for clinicians to get used to
the new test. This has been shown in Swaziland where
the utilisation increased to 73% in the second and third
years after implementation, and in Cape Town, where
the impact on empirical treatment reached its maximum
in the third year after implementation [26, 27].
The lack of association between post-XP empirical
treatment or microbiologically confirmed treatment and
the risk of death was also found by three recent studies
among both ambulant and hospitalized ART naïve pa-
tients [18, 28–30]. However, a recent systematic review
on the impact of tuberculosis nucleic amplification tests,
such as Xpert® MTB/RIF, concluded that the evidence
has been of limited scientific rigour and from a relatively
small number of settings, limiting its validity and
generalisability [13]. We found that CD4 count con-
founded the negative association between empirical treat-
ment and mortality. It is well known that a low CD4
count is a strong risk factor for mortality, and is likely to
be associated with being treated empirically for TB [12].
Our study design was also not optimal to investigate this
association, however, and we may not have captured
potential confounding factors of the relationship between
empirical treatment and mortality, including anemia, co-
morbidities such as malignancies, and others.
The main limitation of this study was the risk of
misclassification bias if clinicians failed to answer the
clinical decision question truthfully due to misunder-
standing of its purpose (whether it might affect the
procedure in the laboratory or be used to review their
performance). This was minimized with continued
training and regular checks of their understanding. More
than half of eligible patients were not sent for an XP;
their higher probability of an EPTB diagnosis suggests a
higher clinical suspicion of extrapulmonary involvement
on the basis of additional information not captured in
our data.
Conclusions
XP usage to aid the diagnosis of smear-negative TB by
experienced clinicians was lower than expected. In those
tested, experienced clinicians mainly used the XP as a
“rule-in” test and only partly as a “rule-out” test. The
lower sensitivity of XP in smear-negative HIV-positive
patients led to the majority of patients still being treated
empirically.
Fig. 2 All-cause mortality in the first 12 months after presentation to the TB clinic among presumptive smear-negative TB patients, stratified by
TB treatment on the basis of microbiological confirmation (positive XP), post-XP empirical treatment (negative or no XP) or no treatment
(negative or no XP). Log-rank test for equality of survivor functions: P 0.01. Confirmed, microbiologically confirmed treatment; Empirical,
post-Xpert® MTB/RIF empirical treatment; None, no treatment
Hermans et al. BMC Infectious Diseases  (2017) 17:433 Page 6 of 8
Abbreviations
aHR: adjusted hazard ratio; aOR: adjusted odds ratio; CD4: CD4+ T cell;
HIV: Human Immunodeficiency Virus; IQR: Interquartile range; MDR: Multi-
drug resistant; N: Number; Rx: Treatment; SD: Standard deviation;
TB: Tuberculosis; WHO: World Health Organization; XP: Xpert MTB/RIF
Acknowledgements
The authors would like to thank the TB/HIV clinic team at the Infectious
Diseases Institute for their input and assistance in this project, and Joseph
Musaazi for his help with data management.
Funding
Xpert® MTB/RIF test cartridges were supplied by a project of the University
of Antwerp funded by the Flemish Interuniversity Council. This study was
supported by the Infectious Diseases Network for Treatment and Research in
Africa (INTERACT) programme, funded by the Netherlands Organization for
Scientific Research – WOTRO Science for Global Development: NACCAP
[grant number W07.05.20100] and the European Union [grant number
SANTE/2006/105–316]. Salary support to SH was provided by the INTERACT
programme followed by a European Union Marie Curie International
Outgoing Fellowship for Career Development [PIOF-GA-2012-332,311].
Support was also provided under the National Institutes of Health (DMID
under the Tuberculosis Clinical Diagnostics Research Consortium [NIH/NIAID],
HHSN272200900050C for YM) and the Office of the Global AIDS Coordinator-
funded Medical Education Partnership Initiative-Medical Education for Ser-
vices to all Ugandans (RFA-TW-10-008) for YM and CSW, and the NIH Fogarty
International Center (D43TW009771) for YM. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
SH, JB and YM conceived and designed the study. SH analysed the data. SH,
JB, OM, FK, BC, CW and RPR were involved in collecting the data. All authors
interpreted the data and critically reviewed the manuscript. SH wrote the
first draft. All authors read and approved the final manuscript.
Competing interests
BC is a member of the editorial board of this journal. The other authors
declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Adult Infectious Diseases Clinic has ongoing approval by the Makerere
University Research Ethics Committee and the Uganda National Council of
Science and Technology to utilize routinely collected data for operational
research purposes. A written consent waiver to do retrospective analysis of
routinely collected data was granted; data were analysed after removal of
unique personal identifiers.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Infectious Diseases Institute, Makerere University College of Health Sciences,
P.O. Box 22418, Kampala, Uganda. 2Department of Internal Medicine, School
of Medicine, Makerere University College of Health Sciences, Kampala,
Uganda. 3Department of Global Health, Academic Medical Center, University
of Amsterdam, Amsterdam Institute for Global Health and Development,
Amsterdam, The Netherlands. 4Institute for Tropical Medicine, University of
Antwerp, Antwerp, Belgium. 5Global Health Institute, University of Antwerp,
Antwerp, Belgium. 6Institute of Public Health, University of Cambridge,
Cambridge, UK. 7Division of Infectious Diseases, Department of Medicine,
Johns Hopkins University School of Medicine, Baltimore, USA.
Received: 10 March 2017 Accepted: 7 June 2017
References
1. World Health Organization. WHO endorses new rapid tuberculosis test.
2010. Available from: http://www.who.int/mediacentre/news/releases/2010/
tb_test_20101208/en/. Accessed on 15/12/2014.
2. World Health Organization. Policy statement: automated real-time nucleic
acid amplification technology for rapid and simultaneous detection of
tuberculosis and rifampicin resistance: Xpert MTB/RIF system.; 2011.
Available from: http://whqlibdoc.who.int/publications/2011/9789241501545_
eng.pdf. Accessed on 31–01-2012.
3. World Health Organization. Automated real-time nucleic acid amplification
technology for rapid and simultaneous detection of tuberculosis and
rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary
and extrapulmonary TB in adults and children. Policy update. Geneva: World
Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/
10665/112472/1/9789241506335_eng.pdf. Accessed on 15/12/2014.
4. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC.
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what
lessons have we learnt and how can we do better? Eur Respir J.
2016;48(2):516–25.
5. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health
impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF:
a dynamic simulation and economic evaluation. PLoS Med.
2012;9(11):e1001347.
6. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, et al.
The impact and cost of scaling up GeneXpert MTB/RIF in South Africa.
PLoS One. 2012;7(5):e36966.
7. Dowdy DW, Davis JL, den Boon S, Walter ND, Katamba A, Cattamanchi A.
Population-level impact of same-day microscopy and Xpert MTB/RIF for
tuberculosis diagnosis in Africa. PLoS One. 2013;8(8):e70485.
8. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al.
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF
testing for tuberculosis in primary-care settings in Africa: a multicentre,
randomised, controlled trial. Lancet. 2014;383(9915):424–35.
9. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al.
Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high
TB and HIV prevalence in South Africa: a pragmatic randomised trial.
PLoS Med. 2014;11(11):e1001760.
10. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M,
Cavalcante S, et al. Impact of replacing smear microscopy with Xpert MTB/
RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-
randomized trial. PLoS Med. 2014;11(12):e1001766.
11. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP,
et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test
for tuberculosis: a cluster-randomised trial embedded in South African roll-
out of Xpert MTB/RIF. Lancet Glob Health. 2015;3(8):e450–7.
doi:10.1016/S2214-109X(15)00100-X.
12. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of
empirical treatment undermine the potential effect of new diagnostic tests for
tuberculosis in high-burden settings? Lancet Infect Dis. 2014;14(6):527–32.
13. Schumacher SG, Sohn H, Qin ZZ, Gore G, Davis JL, Denkinger CM, et al.
Impact of molecular diagnostics for tuberculosis on patient-important
outcomes: a systematic review of study methodologies. PLoS One.
2016;11(3):e0151073.
14. Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JM, Hoepelman AI,
et al. Integration of HIV and TB services results in improved TB treatment
outcomes and earlier, prioritized ART initiation in a large urban HIV clinic in
Uganda. J Acquir Immune Defic Syndr. 2012;60(2):e29–35.
15. Hermans SM, Nasuuna E, Van Leth F, Byhoff E, Schwarz M, Hoepelman A, et
al. Implementation and effect of intensified case finding on diagnosis of
tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort
study. BMC Public Health. 2012;12:674.
16. Nakiyingi L, Bwanika JM, Kirenga B, Nakanjako D, Katabira C, Lubega G, et al.
Clinical predictors and accuracy of empiric tuberculosis treatment among
sputum smear-negative HIV-infected adult TB suspects in Uganda.
PLoS One. 2013;8(9):e74023.
17. Bakari M, Arbeit RD, Mtei L, Lyimo J, Waddell R, Matee M, et al. Basis for
treatment of tuberculosis among HIV-infected patients in Tanzania: the role
of chest x-ray and sputum culture. BMC Infect Dis. 2008;8:32.
Hermans et al. BMC Infectious Diseases  (2017) 17:433 Page 7 of 8
18. Katagira W, Walter ND, Den Boon S, Kalema N, Ayakaka I, Vittinghoff E, et al.
Empiric TB treatment of severely ill patients with HIV and presumed
pulmonary TB improves survival. J Acquir Immune Defic Syndr.
2016;72(3):297–303.
19. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R)
MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in
adults. Cochrane Database Syst Rev. 2014;1:CD009593.
doi:10.1002/14651858.CD009593.pub3.
20. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al.
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the
Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a
multicentre implementation study. Lancet. 2011;377(9776):1495–505.
21. McCarthy KM, Grant AD, Chihota V, Ginindza S, Mvusi L, Churchyard GJ, et
al. Implementation and operational research: what happens after a negative
test for tuberculosis? Evaluating adherence to TB diagnostic algorithms in
South African primary health clinics. J Acquir Immune Defic Syndr. 2016;
71(5):e119–26.
22. Manabe YC, Zawedde-Muyanja S, Burnett SM, Mugabe F, Naikoba S,
Coutinho A. Rapid improvement in passive tuberculosis case detection and
tuberculosis treatment outcomes after implementation of a bundled
laboratory diagnostic and on-site training intervention targeting mid-level
providers. Open Forum Infect Dis. 2015;2(1):ofv030. doi:10.1093/ofid/ofv030.
23. Schumacher SG, Nabeta P, Boehme C, Ellner J, Alland D, Dorman SE, et al. A
multicenter diagnostic accuracy study of the Xpert Ultra for tuberculosis
diagnosis. Conference for Retrovirology and Opportunistic Infections; 13–16
February 2017; Seattle, USA, 2017. Abstract 76LB.
24. Hanrahan CF, Haguma P, Ochom E, Kinera I, Cobelens F, Cattamanchi A, et
al. Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to
Improve Diagnosis of Tuberculosis. Open Forum Infect Dis. 2016;3(2):ofw068.
doi:10.1093/ofid/ofw068.
25. Mbonze NB, Tabala M, Wenzi LK, Bakoko B, Brouwer M, Creswell J, et al.
Xpert((R)) MTB/RIF for smear-negative presumptive TB: impact on case
notification in DR Congo. Int J Tuberc Lung Dis. 2016;20(2):240–6.
26. Sikhondze W, Dlamini T, Khumalo D, Maphalala G, Dlamini S, Zikalala T, et al.
Countrywide roll-out of Xpert((R)) MTB/RIF in Swaziland: the first three years
of implementation. Public Health Action. 2015;5(2):140–6.
27. Hermans S, Caldwell J, Kaplan R, Cobelens F, Wood R. The impact of the
roll-out of rapid molecular diagnostic testing for tuberculosis on empirical
treatment in Cape Town, South Africa. Bull World Health Organ. 2017; E-pub
date 28–04-2017. Available from: http://www.who.int/bulletin/online_first/
BLT.16.185314.pdf?ua=1
28. Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, et al.
Empirical tuberculosis therapy versus isoniazid in adult outpatients with
advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry
open-label randomised controlled trial. Lancet.387(10024):1198–209.
29. Manabe YC, Worodria W, van Leth F, Mayanja-Kizza H, Traore AN, Ferro J, et
al. Prevention of early mortality by presumptive tuberculosis therapy study:
an open label. American Journal of Tropical Medicine and Hygiene:
Randomized Controlled Trial; 2016.
30. Grant A, Charalambous S, Tlali M, Johnson S, Dorman SE, Hoffman C, et al.
Empirical TB Treatment in Advanced HIV Disease: Results of the TB Fast
Track Trial. Conference on Retroviruses and Opportunistic Infections; 22–25
February 2016; Boston, Massachusetts, USA, 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hermans et al. BMC Infectious Diseases  (2017) 17:433 Page 8 of 8
